Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Vascular Inflammation in Rheumatoid Arthritis
NCT02109289Phase 4Terminated
- Sponsor
- Innovaderm Research
- Start
- Apr 2014
- Primary completion
- Nov 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by Innovaderm Research. Primary endpoint: Target to background ratio from the ascending aorta at 16 weeks. Started Apr 2014; status: terminated.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02109289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109289.